As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizable potential payout down the line. | Seattle’s Adaptive Biotechnologies ...
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing ...
Investing.com -- Adaptive Biotechnologies Corp (NASDAQ:ADPT) stock rose 4.3% in Monday premarket trading following the announcement of two non-exclusive agreements with Pfizer Inc (NYSE:PFE) that ...
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid ...
Adaptive Biotechnologies (ADPT) announced two non-exclusive agreements with Pfizer (PFE) to leverage Adaptive’s proprietary T-cell receptor ...
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment ...
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...
SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
On a relatively sleepy day for the market, the biotech enjoyed a decent little price pop on earnings. Its first quarter results topped analyst estimates on both the top and bottom lines. A double beat ...
Shares of Adaptive Biotechnologies (NASDAQ:ADPT) climbed in the morning hours on Friday after Goldman Sachs upgraded the stock to Buy from Neutral, arguing that the cancer test maker operates in an ...
Adaptive Biotechnologies' MRD segment, primarily clonoSEQ, shows growth (24% revenue increase) amid sector challenges. ADPT faces an overall financial decline (21% revenue drop, larger net loss), ...
ADAPTIVE BIOTECH ($ADPT) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.20 per share, beating estimates of -$0.30 by $0. ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback